Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Sintilimab in Advanced HCC
NCT04052152Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, sintilimab in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
anlotinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04052152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052152.